MDCO's once-doomed cangrelor under review by FDA
This article was originally published in Scrip
Executive Summary
The FDA has accepted the new drug application (NDA) for The Medicines Company (MDCO) intravenous antiplatelet cangrelor as a treatment in patients undergoing percutaneous coronary intervention (PCI) and those that require bridging from oral antiplatelet therapy to surgery.